1. Matthews NH, Li WQ, Qureshi AA, et al. Epidemiology of Melanoma. In: Ward WH, Farma JM, eds. Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU): Codon Publications; 2017.
2.
Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer A, et al. Cutaneous melanomas. Oncol Clin Pract 2020; 16: 163–182.
3.
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120–140.
4.
The Global cancer observatory, Globocan, WHO, December 2020 [cited 01.12.2021]. Available from URL: https://gco.iarc.fr/today/en.
5.
Argenziano G, Briatico G, Brancaccio G, et al. Clinical Clues to Avoid Missing Melanoma When Morphology is Not Enough. Dermatol Pract Concept 2021; 11(4): e2021143, doi: 10.5826/dpc.1104143.
6.
Forsea AM. Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities. Dermatol Pract Concep 2020; 10(3): e2020033.
7.
ECIS-European Cancer Information System. Measuring cancer burden and its time trends across Europe [cited 01.01.2019]. Available from URL: https://ecis.jrc.ec.europa.eu.
8.
Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol Online J 2009; 15(11): 1.
9.
Russo T, Lallas A, Brancaccio G, et al. No One Should Die of Melanoma: Time for This Vision to Be Realized? Dermatol Pract Concept 2019; 9(1): 1–3, doi: 10.5826/dpc.0901a01.
10.
Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res 2012; 22(1): 1–8.
11.
Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006; 142(12): 1551–1558.
12.
Segura S, Pellacani G, Puig S, et al. In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy, and histopathologic correlates. Arch Dermatol 2008; 144(10): 1311–1320.
13.
Gajda M, Kaminska-Winciorek G. Do not let to be late: overview of reasons for melanoma delayed diagnosis. Asian Pac J Cancer Prev 2014; 15(9): 3873–3877, doi: 10.7314/apjcp.2014.15.9.3873.
14.
Karabeg R, Lukic D, Janjic Z, et al. The analysis of reasons for malignant skin tumors late diagnosis. Mater Sociomed 2012; 24(2): 73–75, doi: 10.5455/msm.2012.24.73-75.
15.
Geller AC, Koh HK, Miller DR, et al. Use of health services before the diagnosis of melanoma: implications for early detection and screening. J Gen Intern Med 1992; 7(2): 154–157, doi: 10.1007/BF02598004.
16.
Federman DG, Kravetz JD, Kirsner RS. Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol 2002; 46(5): 710–714, doi: 10.1067/mjd.2002.120531.
17.
Argenziano G, Zalaudek I, Hofmann-Wellenhof R, et al. Total body skin examination for skin cancer screening in patients with focused symptoms. J Am Acad Dermatol 2012; 66(2): 212–219, doi: 10.1016/j.jaad.2010.12.039.
18.
Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the inter-net. J Am Acad Dermatol 2003; 48: 679–693.
19.
Rutkowski P, Wysocki P, Kozak K, et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract 2022; 18: 357–392.
20.
Lallas A, Zalaudek I, Apalla Z, et al. Management rules to detect melanoma. Dermatology 2013; 226(1): 52–60, doi: 10.1159/000346645.
21.
Kamińska-Winciorek G, Pilśniak A. The role of dermoscopy in dermato-oncological diagnostics – new trends and perspectives. Nowotwory J Oncol 2021; 71: 103–110, doi: 10.5603/NJO.a2021.0013.
22.
Wysocki WM, Owczarek w, Dyduch G, et al. Postępowanie w przypadku podejrzanych zmian skórnych. Praktyczne wskazówki dla lekarzy specjalności nieonkologicznych. Forum Derm 2021; 7(2): 27–36, doi: 10.5603/FD.2021.0009 (in Polish).
23.
Kulbat A, Richter K, Stefura T, et al. Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases. Curr Oncol 2023; 30(6): 5727–5737, doi: 10.3390/curroncol30060430.
24.
Dzwierzynski WW. Melanoma Risk Factors and Prevention. Clin Plast Surg 2021; 48(4): 543–550, doi: 10.1016/j.cps.2021.05.001.
25.
Lallas A, Apalla Z, Chaidemenos G. New Trends in Dermoscopy to Minimize the Risk of Missing Melanoma. J Skin Cancer 2012; 2012: 820474.
26.
Lallas A, Longo C, Manfredini M, et al. Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ. JAMA Dermatol 2018; 154(4): 414–419, doi: 10.1001/jamadermatol.2017.6447.
27.
Salerni G, Terán T, Alonso C, et al. The role of dermoscopy and digital dermoscopy follow-up in the clinical diagnosis of melanoma: clinical and dermoscopic features of 99 consecutive primary melanomas. Dermatol Pract Concept 2014; 4(4): 39–46, doi: 10.5826/dpc.0404a07.
28.
Moscarella E, Tion I, Zalaudek I, et al. Both short-term and long-term dermoscopy monitoring is useful in detecting melanoma in patients with multiple atypical nevi. J Eur Acad Dermatol Venereol 2017; 31(2): 247–251, doi: 10.1111/jdv.13840.
29.
Lallas A, Apalla Z, Ioannides D, et al. International Dermoscopy Society. Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society. Br J Dermatol 2017; 177(3): 645–655, doi: 10.1111/bjd.15339.
30.
Haenssle HA, Blum A, Hofmann-Wellenhof R, et al. When all you have is a dermatoscope – start looking at the nails. Dermatol Pract Concept 2014; 4(4): 11–20, doi: 10.5826/dpc.0404a02.
31.
Argenziano G, Briatico G, Brancaccio G, et al. Clinical Clues to Avoid Missing Melanoma When Morphology is Not Enough. Dermatol Pract Concept 2021; 11(4): e2021143, doi: 10.5826/dpc.1104143.
32.
Longo C, Scope A, Lallas A, et al. Blue lesions. Dermatol Clin 2013; 31(4): 637–647, doi: 10.1016/j.det.2013.07.001.
33.
Theodosiou G, Johansson I, Hamnerius N, et al. Naevoid Malignant Melanoma: A Diagnosis of a Naevus That You Later Regret. Acta Derm Venereol 2017; 97(6): 745–746, doi: 10.2340/00015555-2634.
34.
Soon SL, Solomon AR Jr, Papadopoulos D, et al. Acral lentiginous melanoma mimicking benign disease: the Emory experience. J Am Acad Dermatol 2003; 48(2): 183–188, doi: 10.1067/mjd.2003.63.
35.
Brinker TJ, Schlager G, French LE, et al. Computerassistierte Hautkrebsdiagnose: Wann kommt künstliche Intelligenz in der Praxis an? [Computer-assisted skin cancer diagnosis: Is it time for artificial intelligence in clinical practice?]. Hautarzt 2020; 71(9): 669–676, doi: 10.1007/s00105-020-04662-8 (in German).